Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Buys 280,183 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock in a transaction that occurred on Friday, November 8th. The stock was purchased at an average cost of $1.50 per share, with a total value of $420,274.50. Following the completion of the acquisition, the chief executive officer now directly owns 211,512,405 shares in the company, valued at $317,268,607.50. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

OPKO Health Trading Up 4.8 %

NASDAQ OPK opened at $1.52 on Friday. The stock has a market cap of $1.06 billion, a P/E ratio of -4.61 and a beta of 1.65. The company has a current ratio of 1.63, a quick ratio of 1.36 and a debt-to-equity ratio of 0.13. The company has a fifty day simple moving average of $1.52 and a two-hundred day simple moving average of $1.42. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.75.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.08. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The firm had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $184.70 million. During the same quarter last year, the company posted ($0.03) earnings per share. The firm’s revenue was down 31.3% compared to the same quarter last year. On average, analysts forecast that OPKO Health, Inc. will post -0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. StockNews.com upgraded OPKO Health to a “sell” rating in a research report on Saturday, July 27th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th. Finally, Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday.

Hedge Funds Weigh In On OPKO Health

A number of large investors have recently added to or reduced their stakes in the stock. CIBC Asset Management Inc boosted its stake in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. Virtu Financial LLC purchased a new position in OPKO Health in the 1st quarter valued at $26,000. Algert Global LLC acquired a new stake in OPKO Health during the 2nd quarter worth $44,000. Headlands Technologies LLC purchased a new stake in shares of OPKO Health during the first quarter worth $47,000. Finally, Private Advisor Group LLC grew its holdings in shares of OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after buying an additional 25,000 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.